Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics reported mature data from its Phase 1b/2a ACCENT trial in advanced pancreatic cancer, showing that five patients achieved a complete response when treated with narmafotinib plus gemcitabine-Abraxane, an unprecedented 7.8% complete response rate in this setting. Independent central review also found a median overall survival of 11.1 months, about two months longer than historical chemotherapy-alone benchmarks and matching survival seen with the recently approved NALIRIFOX regimen, without adding toxicity, and the data will be presented at the American Association of Cancer Research meeting in April 2026.
The updated analysis, based on standardized RECIST 1.1 criteria, also lifted the objective response rate to 35.9% and confirmed that narmafotinib continues to be well tolerated in combination with chemotherapy. These results strengthen Amplia’s clinical case that narmafotinib can enhance standard-of-care treatment in first-line advanced pancreatic cancer and may improve the company’s visibility and strategic positioning as it showcases the data to global oncology experts at the AACR conference.
The most recent analyst rating on (AU:ATX) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australia-based biotechnology company focused on developing targeted cancer therapies. Its lead drug candidate, narmafotinib, is being evaluated in combination with standard chemotherapy for advanced pancreatic cancer, aiming to improve response rates and survival outcomes in a highly aggressive and hard-to-treat indication.
YTD Price Performance: -25.33%
Average Trading Volume: 648,621
Technical Sentiment Signal: Sell
Current Market Cap: A$57.72M
See more data about ATX stock on TipRanks’ Stock Analysis page.